Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bms-223131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.44 |
| ▸ | EEF2K | O00418 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | NEK4 | P51957 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-223131 SCHEMBL30627537 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| Bms-223131 SCHEMBL27618716 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5159321 | 0.94 | CYP2C9 (0.88) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5163058 | 0.94 | CYP2C9 (0.88) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL3275049 | 0.93 | CYP2C9 (0.86) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5158929 | 0.92 | CYP2C9 (0.86) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5159796 | 0.89 | CYP2C9 (0.80) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5160635 | 0.88 | CYP2C9 (0.78) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5159637 | 0.86 | CYP2C9 (0.76) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5161367 | 0.86 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575589-A4 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1133474-B1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1575589-A1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1133474-A4 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040147749-A1 | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-29 | — | — | US | claimed |
| WO-2004058260-A1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-15 | — | — | WO | claimed |
| CN-1129582-C | 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2003-12-03 | — | — | CN | claimed |
| CN-1329599-A | 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2002-01-02 | — | — | CN | claimed |
| EP-1133474-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-19 | — | — | EP | claimed |
| US-6184231-B1 | NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION | BRISTOL-MYERS SQUIBB | 2001-02-06 | — | — | US | claimed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | claimed |
| EP-1575589-B1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1575589-A4 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1133474-B1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1575589-A1 | ATROPISOMERS OF 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6353119-B1 | FROM A SUBSTITUTED COUMARIN AND USING A PHOTOCHEMICAL CYCLIZATION METHOD ON A DIHYDROFURAN INTERMEDIATE | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-05 | — | — | US | disclosed |
| CN-1329599-A | 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 2002-01-02 | — | — | CN | disclosed |
| EP-1133474-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6184231-B1 | NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION | BRISTOL-MYERS SQUIBB | 2001-02-06 | — | — | US | disclosed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147749-A1 | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives | KCNN3, KCNN1, KCNN2 | CYP2C9 475/4885CYP3A4 178/4885CYP2C19 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.